linjc16/ctgov huggingface dataset:
Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic

Study Overview
=================
Brief Summary
-----------------
the audiology has achieved a great advance, where currently speech pathologists act in private clinics and in public services, in addition to schools, colleges and universities. To observe the development of the area of Audiology in Brazil, we note that there is a growing number of new audiology procedures. In 1980 the practice of audiology was limited in hospitals, offices and private clinics, and in 1988 due to a new constitution that devoted attention to protection of health of workers, opened-if more than one field of work, the audiology occupational, because of the hearing losses induced by noise

Detailed Description
-----------------
The area of audiology referred-if the science of hearing, auditory processing and corporal balance. The speech pathologist, Especialista em Audiologia, identifies, assesses and rehabilitation, empowering people with disabilities peripheral or central auditory, influencing the emergence of human communication disorders, as well as the balance disorders

Official Title
-----------------
Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic

Conditions
-----------------
Audiologist, Fortaleza

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the professionals working with clinical audiology Exclusion Criteria: the professionals who do not act in the city of Fortaleza or refuse to sign the Term of Free and Informed Consent

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
speech and language, phonoaudiology, marketing
Microarray Analysis of Gene Expression in Liver Tumors

Study Overview
=================
Brief Summary
-----------------
This study aims to study the gene expression profiles of liver tumors to help us understand their biology, and to find new tumor and treatment markers for liver cancer.

Detailed Description
-----------------
The purpose of this research is to study of the biologic features of liver tissue (by studying their gene expression profiles), so that we can increase our understanding of the processes involved in liver cancer development and growth. This may allow us to identify more effective ways of diagnosing, treating, and predicting the outcome of patients with liver cancer.

Official Title
-----------------
Microarray Analysis of Gene Expression in Liver Tumors

Conditions
-----------------
Liver Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Inclusion Criteria: Patients with liver tumors undergoing partial liver resection, open liver biopsy, and patients undergoing liver transplantation with or without liver tumors at Stanford University Patients older than 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ivabradine in Hemodialysed Patients With Increased Heart Rate

Study Overview
=================
Brief Summary
-----------------
A significant association between resting heart rate (HR) and both all-cause mortality and cardiovascular mortality has been demonstrated in numerous epidemiologic studies for both the general population and for patients with cardiovascular disease. Cardiac disease is the leading cause of death among hemodialysis (HD) patients a recent study reported that the 48-hr mean HR is an independent predictor of cardiovascular events in normotensive hemodialysis patients. Ivabradine, a pure HR lowering agent,acting on If current inhibition has proven beneficial antianginal effects and mortality reduction linked to HR reduction in ischemic patients. Aim: To evaluate the safety and efficacy of ivabradine in normotensive hemodialysed patients with increased pre-dialysis HR (> 80 bpm)

Official Title
-----------------
Efficacy and Safety of Ivabradine in Hemodialysed Patients With Increased Heart Rate

Conditions
-----------------
High Heart Rate

Intervention / Treatment
-----------------
* Drug: Ivabradine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dialysis patients Sinus rhythm Pre-dialytic Heart rate > 80 bpm Exclusion Criteria: Atrial fibrillation/atrial flutter Heart failure Valvular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ivabradine<br> | Drug: Ivabradine<br>* Ivabradine 5 mg BID titrated to 7.5 mg if tolerated<br>|
| Placebo Comparator: Control<br> | Drug: Placebo<br>* Matched placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients that experienced hypotension |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart rate, Dialysis, ESRD, ivabradine
Moxifloxacin vs. Polytrim for Conjunctivitis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare the effect of Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution in treating your child's pink eye. Both these medications are approved by the Food and Drug Administration, for treatment of conjunctivitis. This study will investigate if both of the medications are equally good.

Official Title
-----------------
A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.

Conditions
-----------------
Conjunctivitis

Intervention / Treatment
-----------------
* Drug: moxifloxacin
* Drug: polytrim


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1 - 18 years of age with presumed bacterial conjunctivitis. Exclusion Criteria: Previous antibiotics or to receive systemic antibiotic.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Moxifloxacin Opthalmic solution<br> | Drug: polytrim<br>* 1-2 drops four times a day for 8-10 days.<br>|
| Active Comparator: Polymyxin B-trimethoprim opthalmic solution<br> | Drug: moxifloxacin<br>* 1-2 drops three times a day for 8-10 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Normal Physical Examination of the Eye |  | 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With a Negative Bacterial Culture | Conjunctival swab specimens were inoculated onto tryptic soy agar with 5% sheep blood and GC II agar supplemented with hemoglobin and isovialex with incubation at 35 degrees C in ambient air supplemented with 5% carbon dioxide for 48 hours. S pneumoniae, H influenzai and M Catarrhalis were identified. | 10 days |
En Masse Distaliaztion Via Skeletal Anchorage

Study Overview
=================
Brief Summary
-----------------
Comparing the efficacy and performance of two conventionally anchored distalizers after modifying them to be skeletally anchored. En masse distalization is attempted by consolidating the posterior maxillary segment first premolar to second molar as one unit.

Official Title
-----------------
Evaluation of Two Bone Anchored Appliances for en Masse Distalization of Maxillary Buccal Segment in Class II Patients: A Comparative Clinical Study

Conditions
-----------------
Orthodontic Appliance Complication, Angle Class II Patients, Distalization

Intervention / Treatment
-----------------
* Device: Distalization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Full set of permanent teeth present, except for third molar Bilateral Class II malocclusion with a mesial migration of maxillary posterior teeth No systemic conditions interfering with treatment, as reported by patient No previous Orthodontic treatment Good Oral Hygiene No use of any for of anti-inflammatory drugs Exclusion Criteria: Patient who required surgery to correct skeletal discrepancies Patient with congenital dentoskeletal disorders Missed or Mutilated teeth in Maxillary arch Patients with poor oral hygiene

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Skeletally anchored Distal Jet appliance<br> | Device: Distalization<br>* Distalizing the posterior maxillary segment<br>|
| Active Comparator: Skeletally anchored Hyrax screw distalizer<br> | Device: Distalization<br>* Distalizing the posterior maxillary segment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of distalization | difference in initial and final position of maxillary posterior segment | 6 months |
Retinal Imaging Using NOTAL-OCT V2.5

Study Overview
=================
Brief Summary
-----------------
Primary objectives: To compare between retinal measurements, done by the NOTAL-OCT V2.5 device and a commercial OCT. Secondary objectives: To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula. To evaluate the repeatability of the NOTAL-OCT V2.5

Detailed Description
-----------------
Study population: AMD population - intermediate and advanced AMD (with active and nonactive CNV) DR population. Patient with and without DME

Official Title
-----------------
Retinal Imaging Using NOTAL-OCT V2.5

Conditions
-----------------
AMD

Intervention / Treatment
-----------------
* Device: NOTAL OCT V2.5


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a- Ability and agreement to give informed consent (IC) b -Diagnosis of AMD or DR in SE by OCT c- Ability to undergo OCT scans d- VA of 20/400 (6/120) or better in SE Exclusion Criteria: AMD and DR in the same SE Evidence of macular disease other than AMD or DME in SE Patient with dilated eye(s)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AMD Patients<br>OCT scan | Device: NOTAL OCT V2.5<br>* AMD Patients<br>* Other names: OCT scan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The level of agreement between NOTAL-OCT V2.5 and commercial OCT in detecting fluid | measurements of retinal thickness. | less than an hour |
Minipuberty in Infants Born With Potential Hypogonadism Hypogonadotrope

Study Overview
=================
Brief Summary
-----------------
Disorders of sex development (DSD) occur in 1/3000 births and are defined by variation in aspect of external genital organs, e.g. cryptorchidism, hypospadias and micropenis in male infants and clitoral hypertrophy in female infants. Genetic, hormonal and environmental factors are implicated in DSD. Infants with congenital hypogonadism hypogonadotrope (CHH) can present with DSD. Evaluation of hormonal profile during minipuberty could be of great help to better characterize the etiology of DSD and CHH in particular. Our main objective is to study hormonal profile during the minipuberty of infants born with DSD or born from parents with CHH compared to controls.

Official Title
-----------------
Evaluation of Minipuberty in Infants Born With a Variation in Sexual Development

Conditions
-----------------
DSD, CHH

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infants born with symptoms of DSD infants born from parents with CHH Exclusion Criteria: premature < 35 weeks of gestation male infants with high scrotal cryptorchidism

Ages Eligible for Study
-----------------
Maximum Age: 9 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hormonal changes in blood and in urine during minipuberty (LH, FSH, steroid profile, Testosterone, Estradiol (in girls), AMH, inhibin B) | Reproductive profile: LH and FSH (UI/L) steroid profile (nmol/L) Testosterone and Estradiol (nmol/L) AMH (ng/mL) inhibin B (pg/mL) | at 2, 6 and 9 months of age (window for minipuberty) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quantification of Nitric Oxide metabolites during minipuberty | measurements of Nitrite (NO2-) and nitrate (NO3-) in blood | at 2, 6 and 9 months of age | 
| change in expression of genes involved in the NO pathway | RNA sequencing of samples collected in blood | at birth (if available), 2, 6 and 9 months of age |
Stimulation of Efferent Loop Prior to Ileostomy Closure

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare postoperative ileus between stimulated and unstimulated patients prior to ileostomy closure.

Detailed Description
-----------------
Stimulation was performed ten days prior to the intervention, through the efferent limb of the ileostomy with 500 cc of a thickening substance (saline and nutritional thickener)

Conditions
-----------------
Ileostomy; Complications

Intervention / Treatment
-----------------
* Procedure: Procedure/Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: protective ileostomy after rectal cancer surgery Exclusion Criteria: under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: No stimulation<br>unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb. | Procedure: Procedure/Surgery<br>* daily stimulation of efferent loop prior to surgery (ileostomy closure)<br>* Other names: Stimulation;|
| Experimental: Stimulation<br>stimulation of the efferent limb of the ileostomy prior to ileostomy closure. | Procedure: Procedure/Surgery<br>* daily stimulation of efferent loop prior to surgery (ileostomy closure)<br>* Other names: Stimulation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative ileus |  | within the first days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ileostomy closure,postoperative ileus,stimulation ileostomy
Uterus Transplantation From Live Donor

Study Overview
=================
Brief Summary
-----------------
Uterus transplantation, as a possible future treatment for uterine factor infertility, has been developed in animal species during the last decade. The study protocol includes transplantation of the uterus from a live donor (mother, relative, friend) into women with absolute uterine factor infertility (lack of uterus from birth or due to life saving hysterectomy).The recipient will be treated by standard immunosuppression and transfer of embryos (acquired by IVF before surgery) will be attempted when at least 12 months have passed from transplantation. Approval for a case series including up to 10 patients has been acquired.

Detailed Description
-----------------
The study is ongoing, with inclusion of 9 patients.

Official Title
-----------------
Prospective Case Series of Human Uterus Transplantation From Live Donor

Conditions
-----------------
Primary Uterine Infertility

Intervention / Treatment
-----------------
* Procedure: uterine transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: less than 39 years good general health Exclusion Criteria: poor ovarian resaerve or older than 39 years systemic or psychiatric disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Uterine transplantation<br>Patients undergo transplantation of the uterus from live donor. | Procedure: uterine transplantation<br>* Transplantation of the uterus from live donor and IVF treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surviving transplants (12 months) |  | up to 3 years after transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate |  | up to 3 years after transplantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
uterus, transplantation, infertility
Clinical Efficacy of OneTouch® Verio™IQ Meter

Study Overview
=================
Brief Summary
-----------------
Diabetes mellitus is one of the most prevalent disease in the western world. The control of glucose levels has a big impact in the prevention of diabetes complications. The measure of glucose levels in capillary blood with glucometers is the gold standard to measure and control the glucose levels. Nowadays the glucometers become to more precise and sophisticated devices. One of the most notables advance is the inclusion of software that cam predicts glucose trends. This software has not be tested in routine clinical practice.

Official Title
-----------------
Clinical Efficacy of OneTouch® Verio™IQ Meter

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: Verio Pattern Alert® activated
* Device: Verio Pattern Alert® deactivated


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient diagnosed with diabetes mellitus 1 or 2 Treatment with insulin regimen during at least 12 months Capability of performed 3 glucose measurement per day Levels of glycated hemoglobin (A1C) less than 10% Exclusion Criteria: Patients diagnosed of mental disorders Patients included in structured therapeutic health 6 months before the inclusion Patients included in any clinical trial in the 4 months before the inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Verio Pattern Alert® activated<br>In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends. | Device: Verio Pattern Alert® activated<br> <br> |
| Active Comparator: Verio Pattern Alert® deactivated<br>In this cohort, the patients will monitoring the glucose levels with capillar glucometer. | Device: Verio Pattern Alert® deactivated<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of hypoglycemic events | Glucose levels under 70 mg/dL with or without clinical manifestation | 20 months |